Leading developer of
personal care products DS Healthcare Group announced it has appointed Aptiv
Solutions as its clinical research organization (CRO) for a proprietary topical
prescription treatment. The drug, if approved, will be positioned as a
frontline therapy against hair loss.
DS Healthcare’s
Investigational New Drug Application (IND) for this proprietary topical hair
loss treatment will be prepared by Aptiv Solutions for submission to the FDA.
Only one other topical hair loss treatment has been approved by the FDA to
date. Additionally, Aptiv Solutions will conduct a Gap analysis to ensure that
DS Healthcare’s operations are in line with regulatory requirements for drug
approval.
A leading global CRO with
extensive global drug development and trial management expertise, Aptiv
Solutions has conducted more than 2,600 clinical trials and has assisted with
more than 140 FDA and European Union drug and biologic approvals and more than
700 medical device approvals and clearances.
Recently, DS Healthcare
announced its intention to submit an IND to the FDA – a move that follows the
company’s patent application filing with the U.S. Patent and Trademark Office
for its invention of the prescription hair loss treatment.
For more information, visit
www.dslaboratories.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
